All In Biotech

Drug Trial Radar · NCT07914673

Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 25, 2026

Primary completion

Feb 1, 2027

Study completion Sep 25, 2027

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Bill and Melinda Gates Foundation
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to better understand how the immune system responds to vaccination against influenza and rabies. Researchers want to study how immune responses develop and change over time in the blood and in the lymph nodes that drain the vaccination site, following vaccination with two vaccines licensed by the U.S. Food and Drug Administration (FDA): the seasonal trivalent influenza vaccine (TIV) and the rabies vaccine (RabAvert). By studying these samples, researchers hope to learn how the body produces high-quality, long-lasting antibody and memory immune responses after vaccination. The study will also compare immune responses in younger adults to immune responses in older adults, because prior research suggests that the immune system's ability to respond to vaccination weakens with age.

Conditions

  • Healthy Adult Participants
  • Age 65 and Older
  • Age 18 to 40
  • Immunology

Interventions

  • Trivalent inactivated influenza vaccineBiological

    Standard, seasonal flu vaccines

  • RabAvertBiological

    Rabies vaccine for pre-exposure

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rabies-specific antibody titers at day 29 compared to pre-vaccination baseline.Time frame: From vaccination day 1 to day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.